Bifogade filer
AegirBio_Q1 2024
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
SAMMANFATTNING AV DELÅRSRAPPORTEN
Med bolaget eller AegirBio AB avses AegirBio AB med organisationsnummer 559222-2953
Första kvartalet i koncernen jämfört med samma period 2023
· Totala intäkter uppgick till 1,6 (0) MSEK.
· Resultatet före skatt uppgick till -5,2 (-15,6) MSEK.
· Kassabehållningen var vid slutet av kvartalet 0,2 (-47,9) MSEK.
· Resultat per aktie* -0,16 (-0,69) SEK.
· Soliditeten uppgick** per den 31 mars 2024 till -21 (42) %.
Första kvartalet i moderbolaget jämfört med samma period 2023
· Totala intäkter uppgick till 4,0 (0)MSEK.
· Resultatet före skatt uppgick till -0,2 (-5,7) MSEK.
· Kassabehållningen var vid slutet av kvartalet 0,0 (44,7).
Marco Witteveen – CEO
As we analyse our Q1 report, it's imperative to acknowledge the substantial progress we've achieved, and the valuable insights gleaned from the data.
I'd like to highlight a significant entry in our financials: the invoicing to RADx in March, which has been properly documented as other income. This transaction underscores our dedication to diversifying revenue streams and nurturing strategic partnerships, including potential grants, to fortify our foundation for future expansion.
Addressing a potentially concerning point: our cash balance on March 31st was 0.2 MSEK. While this figure may raise questions, it doesn't fully reflect our financial standing. We've taken measures to reduce costs while simultaneously enhancing effectiveness and efficiency. Additionally, we're proactively managing cash flow, leveraging our RADx project and our financing deal with Atlas to mitigate short-term fluctuations.
Shifting focus to operational accomplishments, I'm pleased to announce the successful completion of our first milestone in April. This achievement signifies a significant advancement in our journey, showcasing our capacity to execute our strategic roadmap and deliver tangible outcomes.
Looking ahead, I am eager to collaborate with our newly appointed board members, Jens Umehag (chairman), Michael Schwartz, and William Ferenczy, alongside our esteemed existing board members Fredrik Häglund and William Vickery. Their extensive experience in business, diagnostic business, and oral health will undoubtedly enrich our strategic discussions and decision-making processes.
As we navigate the intricacies of the business landscape, let's maintain our steadfast commitment to our objectives and strive for excellence. With our collective dedication and resilience, I'm confident that we'll continue charting a path toward sustainable success.
Denna information är sådan som AegirBio är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning (EU nr 596/2014). Informationen lämnades, genom angiven kontaktpersons försorg, för offentliggörande 2024-05-17 08:22 CET.